Feb 12 (Reuters) - Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condition. (Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,089 JPY | -0.02% | +0.49% | +0.86% |
Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,089 JPY | -0.02% | +0.49% | 40.76B | ||
2,686 PTS | +0.86% | +2.29% | - | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.86% | 40.76B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- US FDA approves Takeda's therapy for allergic inflammation in esophagus